123.10
-14.34 (-10.43%)
| Previous Close | 137.44 |
| Open | 132.34 |
| Volume | 4,166,691 |
| Avg. Volume (3M) | 1,032,436 |
| Market Cap | 12,354,742,272 |
| Price / Earnings (TTM) | 32.91 |
| Price / Earnings (Forward) | 19.76 |
| Price / Sales | 5.38 |
| Price / Book | 4.69 |
| 52 Weeks Range | |
| Earnings Date | 4 May 2026 |
| Profit Margin | 12.68% |
| Operating Margin (TTM) | 4.14% |
| Diluted EPS (TTM) | 2.95 |
| Quarterly Revenue Growth (YOY) | 11.10% |
| Quarterly Earnings Growth (YOY) | -81.80% |
| Total Debt/Equity (MRQ) | 19.45% |
| Current Ratio (MRQ) | 3.13 |
| Operating Cash Flow (TTM) | 529.90 M |
| Levered Free Cash Flow (TTM) | 235.48 M |
| Return on Assets (TTM) | 8.75% |
| Return on Equity (TTM) | 12.43% |
Market Trend
| Short Term | Medium Term | ||
| Industry | Drug Manufacturers - Specialty & Generic (US) | Mixed | Mixed |
| Drug Manufacturers - Specialty & Generic (Global) | Bullish | Mixed | |
| Stock | Neurocrine Biosciences, Inc. | Bearish | Bullish |
AIStockmoo Score
| Analyst Consensus | 1.0 |
| Insider Activity | -1.5 |
| Price Volatility | 1.0 |
| Technical Moving Averages | -2.5 |
| Technical Oscillators | -0.5 |
| Average | -0.50 |
|
Neurocrine Biosciences Inc engages in the discovery, development, and commercialization of drugs for the treatment of neurological and endocrine-related diseases and disorders in the United States. The company's products include INGREZZA for tardive dyskinesia and chorea associated with Huntington's disease; ALKINDI for adrenal insufficiency; Efmody capsules for classic congenital adrenal hyperplasia; Orilissa tablets for endometriosis; and Oriahnn capsules to treat uterine fibroids. |
|
| Sector | Healthcare |
| Industry | Drug Manufacturers - Specialty & Generic |
| Investment Style | Mid Core |
| % Held by Insiders | 1.06% |
| % Held by Institutions | 98.86% |
| 52 Weeks Range | ||
| Price Target Range | ||
| High | 204.00 (Citigroup, 65.72%) | Buy |
| Median | 177.00 (43.79%) | |
| Low | 140.00 (BMO Capital, 13.73%) | Hold |
| Average | 177.57 (44.25%) | |
| Total | 11 Buy, 3 Hold | |
| Avg. Price @ Call | 133.20 | |
| Firm | Date | Target Price | Call | Price @ Call |
|---|---|---|---|---|
| Wells Fargo | 13 Feb 2026 | 175.00 (42.16%) | Buy | 123.10 |
| BMO Capital | 12 Feb 2026 | 140.00 (13.73%) | Hold | 123.10 |
| Citigroup | 12 Feb 2026 | 204.00 (65.72%) | Buy | 123.10 |
| HC Wainwright & Co. | 12 Feb 2026 | 192.00 (55.97%) | Buy | 123.10 |
| 17 Dec 2025 | 198.00 (60.84%) | Buy | 141.70 | |
| Needham | 12 Feb 2026 | 185.00 (50.28%) | Buy | 123.10 |
| RBC Capital | 12 Feb 2026 | 177.00 (43.79%) | Buy | 123.10 |
| 08 Dec 2025 | 180.00 (46.22%) | Buy | 154.99 | |
| Wedbush | 12 Feb 2026 | 151.00 (22.66%) | Buy | 123.10 |
| UBS | 23 Jan 2026 | 178.00 (44.60%) | Buy | 136.18 |
| JP Morgan | 12 Jan 2026 | 177.00 (43.79%) | Buy | 132.66 |
| Morgan Stanley | 08 Jan 2026 | 175.00 (42.16%) | Hold | 135.57 |
| Truist Securities | 08 Jan 2026 | 169.00 (37.29%) | Buy | 135.57 |
| Mizuho | 12 Dec 2025 | 175.00 (42.16%) | Hold | 152.80 |
| Stifel | 11 Dec 2025 | 188.00 (52.72%) | Buy | 154.75 |
| TD Cowen | 05 Dec 2025 | 200.00 (62.47%) | Buy | 155.51 |
| Show more | ||||
No data within this time range.
The support, resistance and trendline levels presented has been generated by an artificial intelligence (AI) model and should be interpreted with caution.
Portfolio
| Realized Profit | - |
| Unrealized Profit | - |
| Dividend Received 2026 | - |
| Total Profit | - |
| Avg. Return | - |
| Quantity (Buy) | - |
| Avg. Price (Buy) | - |
| Quantity (Sold) | - |
| Avg. Price (Sold) | - |